The dismissal of hundreds of Zofran birth defect lawsuits was upheld by a federal appeals court which determined GlaxoSmithKline did not have the authority to change the drug's label warnings.
A federal judge has ruled in favor of GlaxoSmithKline, saying Zofran birth defect lawsuits are preempted by federal law due to the FDA's refusal to update the label warnings.
After a number of delays, the first Zofran birth defects bellwether trial is expected to begin in October 2021.
The makers of Zofran argue that a recent FDA rejection of calls to investigate old data on whether it causes birth defects gives the company protection from hundreds of lawsuits.
The first Zofran bellwether trial over claims the drug causes birth defects has been delayed indefinitely due to the coronavirus pandemic.
The first bellwether trial for Zofran birth defect lawsuits has been delayed until May while the FDA considers a citizen's petition by GlaxoSmithKline on whether label warnings on the drug…
Following a recent Supreme Court ruling, a federal judge is revisiting whether Zofran birth defect lawsuits should proceed as planned.
Zofran lawsuits are continuing forward after a federal judge rejected calls by GlaxoSmithKline for a summary judgment in the manufacturer's favor.
A new study shows a link between Zofran use during pregnancy and an increased risk of oral cleft defects.
A motion to dismiss all Zofran lawsuits claims that the FDA never allowed the manufacturer to put birth defect warning labels on the medication.
